This study investigates a condition related to CD73 enzyme activity. The purpose of this study is to evaluate how this investigational medication works alone and in combination with other treatments.
The study will generally focus on assessing the safety and tolerability of the investigational medication. It will also look at how well the medication works in treating the condition.
- Who can participate: Adults with advanced or metastatic solid tumors, such as NSCLC and PDAC, may be eligible. Participants should have measurable lesions and meet other health criteria.
- Study details: Participants will receive either the investigational medication alone or in combination with other treatments. A placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine, may be used in the study.
How understandable was the trial content above?
Hard to understand
Easy to understand